Skip main navigation

Antibiotic treatment for this case

Treatment for Bill Jenkins.
Black and white image of a key board with the word
© BSAC

The main facts that influence targeted therapy are:

  • Mr Jenkins had a (severe) urinary sepsis and we have good evidence of the etiological agent: an ESBL-producing E. coli

  • Although he is still febrile, the clinical course is favourable

  • No evidence of abscess or urinary obstruction has been found

Considering all these facts, Mr. Jenkins probably benefits from:

  • Continuing intravenous antibiotic therapy, at least until he is afebrile

  • Continuing therapy with a single antibiotic

  • Narrowing antimicrobial spectrum

Although probably the most active ß-lactam among the choices is meropenem, carbapenem is one of the most valuable drugs available in the antibiotic armamentarium and should be protected whenever possible.

Carbapenem-sparing strategies are needed in an era of increasing antimicrobial resistance. In this regard, as we seek to treat a urinary tract infection, which is a “low-risk” source provided there is no abscess nor obstruction and that the patient has clinically improved, amoxicillin/clavulanate (if the intravenous presentation is available) or piperacillin/tazobactam could be appropriate treatment options. Since we do not need anti-Pseudomonas activity, amoxicillin/clavulanate would be our choice if we were willing to continue therapy with a ß-lactam. In addition it has the advantage of an easy IV to PO switch.

Mr Jenkins could also be treated using non ß-lactam mono therapy with either amikacin or TMP/SMX.

Since Mr Jenkins is elderly, I would avoid amikacin if possible due to is nephron and ototoxicity.

TMP/SMX would be preferred to amikacin especially when the patient is ready for the IV to PO switch. In addition, TMP/SMX would be a better option than amikacin and even that ß-lactam if a prostate involvement (prostatitis) is suspected given its PK/PD properties. 

You may find the paper from the Scottish Antimicrobial Prescribing Group (SAPG) which provides advice for optimising antimicrobial prescribing for multi-drug resistant Gram-negative bacteria useful.

© BSAC
This article is from the free online

Challenges in Antibiotic Resistance: Gram Negative Bacteria

Created by
FutureLearn - Learning For Life

Our purpose is to transform access to education.

We offer a diverse selection of courses from leading universities and cultural institutions from around the world. These are delivered one step at a time, and are accessible on mobile, tablet and desktop, so you can fit learning around your life.

We believe learning should be an enjoyable, social experience, so our courses offer the opportunity to discuss what you’re learning with others as you go, helping you make fresh discoveries and form new ideas.
You can unlock new opportunities with unlimited access to hundreds of online short courses for a year by subscribing to our Unlimited package. Build your knowledge with top universities and organisations.

Learn more about how FutureLearn is transforming access to education